HomeComparePOLBF vs MO

POLBF vs MO: Dividend Comparison 2026

POLBF yields 3344.48% · MO yields 9.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 POLBF wins by $1284463355857.08M in total portfolio value
10 years
POLBF
POLBF
● Live price
3344.48%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1284463355857.10M
Annual income
$1,213,110,815,498,324,000.00
Full POLBF calculator →
MO
Altria Group Inc.
● Live price
9.11%
Share price
$44.80
Annual div
$4.08
5Y div CAGR
4.3%
Payout ratio
78%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$4,052.72
Full MO calculator →

Portfolio growth — POLBF vs MO

📍 POLBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPOLBFMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, POLBF + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
POLBF pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

POLBF
Annual income on $10K today (after 15% tax)
$284,280.94/yr
After 10yr DRIP, annual income (after tax)
$1,031,144,193,173,575,300.00/yr
MO
Annual income on $10K today (after 15% tax)
$774.11/yr
After 10yr DRIP, annual income (after tax)
$3,444.81/yr
At 15% tax rate, POLBF beats the other by $1,031,144,193,173,571,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of POLBF + MO for your $10,000?

POLBF: 50%MO: 50%
100% MO50/50100% POLBF
Portfolio after 10yr
$642231677928.57M
Annual income
$606,555,407,749,164,000.00/yr
Blended yield
94.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

POLBF
No analyst data
Altman Z
39.8
Piotroski
1/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
+36.7% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

POLBF buys
0
MO buys
0
No recent congressional trades found for POLBF or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPOLBFMO
Forward yield3344.48%9.11%
Annual dividend / share$2.00$4.08
Payout ratio50%78%
1-year div growth0%4.1%
5-year div CAGR0%4.3%
Portfolio after 10y$1284463355857.10M$27.7K
Annual income after 10y$1,213,110,815,498,324,000.00$4,052.72
Total dividends collected$1279557275592.29M$20.9K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: POLBF vs MO ($10,000, DRIP)

YearPOLBF PortfolioPOLBF Income/yrMO PortfolioMO Income/yrGap
1← crossover$345,148$334,448.16$10,740$949.88+$334.4KPOLBF
2$11,157,548$10,788,239.94$11,601$1,086.84+$11.15MPOLBF
3$337,872,856$325,934,279.31$12,608$1,250.75+$337.86MPOLBF
4$9,585,767,941$9,224,243,985.35$13,792$1,448.20+$9585.75MPOLBF
5$254,836,586,625$244,579,814,927.95$15,190$1,687.69+$254836.57MPOLBF
6$6,349,429,806,239$6,076,754,658,549.98$16,851$1,980.28+$6349429.79MPOLBF
7$148,295,333,941,378$141,501,444,048,701.88$18,838$2,340.48+$148295333.92MPOLBF
8$3,247,334,232,557,481$3,088,658,225,240,206.50$21,230$2,787.44+$3247334232.54MPOLBF
9$66,684,617,157,738,690$63,209,969,528,902,180.00$24,130$3,346.72+$66684617157.71MPOLBF
10$1,284,463,355,857,104,100$1,213,110,815,498,324,000.00$27,676$4,052.72+$1284463355857.08MPOLBF

POLBF vs MO: Complete Analysis 2026

POLBFStock

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an in­licensed first­in­class intranasally administered RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro­ and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Full POLBF Calculator →

MOConsumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →
📬

Get this POLBF vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

POLBF vs SCHDPOLBF vs JEPIPOLBF vs OPOLBF vs KOPOLBF vs MAINPOLBF vs PMPOLBF vs BTIPOLBF vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.